Instil Bio Inc reports results for the quarter ended in September - Earnings Summary
Brief: Instil Bio Reports Third Quarter 2022 Financial Results
Instil Bio Inc expected to post a loss of 44 cents a share - Earnings Preview
Instil Bio plunges after brokerages turn bearish on trial enrolment pause
U.S. STOCKS ON THE MOVE-Insperity, Nikola, First Solar
Instil Bio hits record low on pausing enrollment in cancer therapies' trials
U.S. STOCKS ON THE MOVE-Natgas, Wynn Resorts, Ascendis Pharma
U.S. STOCKS ON THE MOVE-Terran Orbital, SunCoke Energy, Alzamend Neuro
Instil Bio slumps on pausing enrollment in cancer therapies' trials
Brief: Instil Bio To Voluntary Pause Enrollment In Ongoing Clinical Trials Related To Manufacturing
Brief: Instil Bio Announces Appointment Of Tim Moore As Chief Operating Officer
Brief: Instil Bio reports Q2 results
Instil Bio Inc expected to post a loss of 41 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Twitter Inc, Raytheon Technologies, Autodesk Inc, Tesla Inc
Brief: Instil Bio Announces IND Clearance Of First CoStAR-TIL Program, Itil-306, Designed To Enhance Activity In Tumor Microenvironment
U.S. RESEARCH ROUNDUP-Dollar Tree, Ulta Beauty, VMware
Brief: Instil Bio Reports First Quarter Net Loss Per Share Of $0.42
Instil Bio Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Instil Bio Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Update